Antimicrobial Agents Practice Questions

Q: Which of the following drugs is least commonly used as first -line therapy for uncomplicated urinary tract infections ?

Fluoroquinolones. ***Fluoroquinolones*** - Due to their potential for **serious side effects**, such as **tendonitis**, **tendon rupture**, and **peripheral neuropathy**, the FDA has restricted their use for uncomplicated urinary tract infections. - They are typically reserved for **complicated infections**, such as **pyelonephritis**, because they should be preserved for more severe conditions to prevent the development of **antibiotic resistance**. *Nitrofurantoin* - This is a standard **first-line agent** for the treatment of uncomplicated **cystitis** due to its high concentration in the urine. - It has a low rate of resistance and is generally well-tolerated, making it an excellent choice for outpatient therapy. *Sulfonamides* - Trimethoprim-sulfamethoxazole (TMP-SMX) is widely recommended as a **first-line treatment** for uncomplicated UTIs in areas where resistance rates are known to be low. - It is effective against most common uropathogens, particularly **Escherichia coli**. *Fosfomycin* - Often administered as a single-dose therapy, **fosfomycin** is an approved **first-line agent** for uncomplicated lower urinary tract infections. - It is highly effective due to its ability to maintain high concentrations in the bladder and its unique mechanism of action which helps overcome **multidrug resistance**.

Q: A wound swab reveals gram-positive cocci in clusters, catalase-positive, sensitive to Cefoxitin and Oxacillin. What is the drug of choice?

Cloxacillin. ***Cloxacillin*** - The organism identified is a **Methicillin-Sensitive Staphylococcus aureus (MSSA)**, as indicated by the **positive sensitivity to Cefoxitin and Oxacillin**, which are used to test for methicillin resistance. - **Cloxacillin** (or other penicillinase-resistant penicillins like Nafcillin or Oxacillin) is the drug of choice for MSSA due to superior efficacy compared to broader-spectrum alternatives. *Ceftriaxone* - This is a **third-generation cephalosporin** that lacks robust activity against MSSA compared to anti-staphylococcal penicillins. - It is not the preferred agent for **staphylococcal infections** unless there is a specific contraindication to penicillins or in specialized clinical contexts. *Vancomycin* - This drug is indicated as the first-line treatment for **Methicillin-Resistant Staphylococcus aureus (MRSA)**. - It has a slower bactericidal effect compared to **beta-lactams** and is reserved for cases of penicillin allergy or resistant strains. *Amoxicillin/Clavulanate* - While this combination is effective against many beta-lactamase-producing bacteria, it is not the gold-standard treatment for **severe S. aureus infections**. - It is typically utilized for polymicrobial infections or oral step-down therapy rather than preferred IV treatment for MSSA.

Q: Match the following antibiotic with its most commonly associated organism: 1. Streptomycin a. Streptococcal pharyngitis 2. Amoxicillin b. H. pylori 3. Doxycycline c. Mycobacterium tuberculosis 4. Clarithromycin d. Chlamydia trachomatis

1-c, 2-a, 3-d, 4-b. ***1-c, 2-a, 3-d, 4-b*** - **Streptomycin** is a classic second-line agent used specifically for the treatment of **Mycobacterium tuberculosis**. - **Amoxicillin** is a first-line penicillin antibiotic frequently used to treat **Streptococcal pharyngitis** caused by Group A Streptococcus. - **Doxycycline** is the preferred treatment for **Chlamydia trachomatis** infections, an obligate intracellular bacteria. - **Clarithromycin** is a key component in the triple therapy regimen used to eradicate **H. pylori** in peptic ulcer disease. *1-c, 2-b, 3-d, 4-a* - While correctly matching **Streptomycin** and **Doxycycline**, it incorrectly assigns **Amoxicillin** to **H. pylori** (which requires a specific macrolide or nitroimidazole combination) and **Clarithromycin** to **Streptococcal pharyngitis**. - **Clarithromycin** is not the standard first-line treatment for uncomplicated **pharyngitis** unless the patient has a severe penicillin allergy. *1-a, 2-c, 3-b, 4-d* - This pairing is incorrect as **Streptomycin** is essential for **Mycobacterial** infections, not **Streptococcal pharyngitis**. - **Doxycycline** is not indicated for **H. pylori**, and **Amoxicillin** is not the drug of choice for **Mycobacterium tuberculosis**. *1-d, 2-a, 3-c, 4-b* - This option incorrectly lists **Streptomycin** as the treatment for **Chlamydia**, while it is primarily an anti-tuberculosis agent. - It also suggests **Doxycycline** treats **Mycobacterium tuberculosis**, which is not clinically standard for TB therapy.

Q: Regarding ESBL-producing organisms and their treatment, which of the following statements are correct? 1. 1st generation cephalosporins such as Cefazolin retain activity against ESBL producers, unlike 3rd generation 2. Carbapenems have proven clinical efficacy against ESBL-producing organisms 3. The beta-lactamase enzyme responsible for ESBL resistance is encoded on transferable plasmids 4. Piperacillin-Tazobactam is a reliable and effective alternative to Carbapenems

2, 3 and 4 only. ***2, 3 and 4 only*** - Carbapenems are the **drug of choice** for serious **Extended-Spectrum Beta-Lactamase (ESBL)** infections, as they are highly stable against hydrolysis by these beta-lactamases. - The resistance genes for ESBL are located on **plasmids**, allowing for rapid **horizontal gene transfer** between bacterial species, contributing to their widespread dissemination. - While the landmark MERINO trial showed higher mortality with **Piperacillin-Tazobactam** compared to meropenem for *E. coli* or *Klebsiella* bloodstream infections, it is still considered a potentially effective, **carbapenem-sparing alternative** in specific clinical scenarios (especially non-bloodstream infections or if the isolate is susceptible at a high inoculum). *1, 2 and 4 only* - 1st generation cephalosporins like **Cefazolin** are typically hydrolyzed by ESBLs and are not considered effective for treating invasive ESBL-producing infections. - This option incorrectly includes the assertion regarding 1st generation cephalosporins, which contradicts standard susceptibility patterns for ESBL-producing organisms. *1, 2 and 3 only* - Statement 4 is generally accepted as a valid, though nuanced, consideration in modern antibiotic stewardship programs (carbapenem-sparing strategies). - This option excludes Piperacillin-Tazobactam, which is increasingly utilized as a viable alternative for confirmed susceptible isolates, whereas statement 1 is factually incorrect regarding ESBL activity. *1, 2, 3 and 4 all* - Statement 1 is incorrect because **1st generation cephalosporins** (like Cefazolin) are poor choices for ESBL-producing organisms as they are readily hydrolyzed by the ESBL enzymes and are clinically ineffective. - Because Statement 1 is false, any option set including it must be incorrect.

Q: A patient is diagnosed with invasive mucormycosis following COVID-19 infection. Which of the following antifungal agents has NO activity against Mucor species and should be avoided?

Voriconazole. ***Voriconazole*** - Voriconazole is a triazole antifungal that lacks significant activity against the **Mucorales** order, which causes mucormycosis. - Clinical guidelines state it should be avoided, as it may even promote the development of **breakthrough fungal infections** by eradicating competing fungal flora like *Aspergillus*. *Isavuconazole* - This agent is a second-line, extended-spectrum triazole that demonstrates efficacy in treating **invasive mucormycosis**. - It is often used for patients who cannot tolerate polyenes or as step-down therapy after initial stabilization. *Posaconazole* - Posaconazole is an azole with demonstrated activity against **Mucorales** species and is approved for use in the treatment of mucormycosis. - It is frequently utilized as **salvage therapy** or for long-term step-down treatment following initial induction therapy. *Liposomal Amphotericin B* - This is the **first-line treatment** of choice for invasive mucormycosis due to its potent fungicidal activity against these pathogens. - It is preferred because it achieves high concentrations in affected tissues with a relative reduction in **nephrotoxicity** compared to non-liposomal formulations.

Q: What is the mechanism of action of Pretomanid under the BPaLM regimen?

Inhibition of mycolic acid synthesis. ***Inhibition of mycolic acid synthesis*** - Pretomanid is a **nitroimidazooxazine** that acts as a prodrug, which is activated by the mycobacterial deazaflavin-dependent nitroreductase enzyme (Ddn). - Once activated, it interferes with **mycolic acid synthesis** and also generates reactive nitrogen species that lead to the inhibition of cellular respiration and ATP depletion in both actively replicating and dormant **Mycobacterium tuberculosis**. *Inhibition of ATP synthase* - This mechanism is specific to **bedaquiline**, another component of the BPaLM regimen, which targets the proton pump of the mycobacterial ATP synthase. - Inhibition of this enzyme leads to the rapid depletion of intracellular ATP, resulting in bacteriostasis and eventual cell death. *Inhibition of RNA polymerase* - This is the primary mechanism of action for **rifamycins** (such as Rifampicin), which bind to the beta unit of RNA polymerase. - By preventing transcription, Rifampicin effectively halts bacterial protein synthesis. *Inhibition of arabinoglycan synthesis* - This mechanism is characteristic of **ethambutol**, which inhibits the arabinosyl transferase enzymes involved in cell wall synthesis. - Disruption of arabinoglycan synthesis weakens the mycobacterial cell wall, making the organism more susceptible to other antibiotics.

Q: Which of the following is a known side effect of zidovudine?

Granulocytopenia. Zidovudine (AZT) is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) used in the management of HIV/AIDS. The correct answer is Granulocytopenia because the most significant and dose-limiting toxicity of zidovudine is bone marrow suppression. 1. Why Granulocytopenia is correct: Zidovudine inhibits DNA polymerase-gamma in host cells, leading to mitochondrial toxicity and interference with rapidly dividing cells [1], [2]. This results in significant myelosuppression, manifesting primarily as anemia (macrocytic) and granulocytopenia/neutropenia. This effect is additive when used with other myelosuppressive drugs like ganciclovir or trimethoprim-sulfamethoxazole. 2. Why other options are incorrect: * Headache and Myalgia (Options A & B): While these can occur as non-specific constitutional symptoms during the initiation of therapy, they are not the "signature" or dose-limiting toxicities tested in competitive exams. (Note: Zidovudine causes a specific myopathy, but granulocytopenia is the more classic hematological side effect). * Rashes (Option D): Rashes are more characteristic of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) like Nevirapine (which can cause Stevens-Johnson Syndrome) or the NRTI Abacavir (hypersensitivity reaction). High-Yield Clinical Pearls for NEET-PG: * Mnemonic: Zidovudine causes "Zapped" Bone Marrow (Anemia and Neutropenia). * Drug of Choice: Zidovudine is the preferred drug for preventing vertical transmission (mother-to-child) of HIV during pregnancy and labor. * Lactic Acidosis: Like all NRTIs, it carries a risk of lactic acidosis and hepatic steatosis [2]. * Monitoring: Patients on AZT require regular monitoring of Hemoglobin and Absolute Neutrophil Count (ANC).

Q: Ethambutol is safer in a patient with which of the following conditions?

Liver disease. **Explanation:** The correct answer is **Liver disease** because Ethambutol is primarily excreted unchanged by the kidneys (approx. 80%) and undergoes minimal hepatic metabolism. Unlike other first-line anti-tubercular drugs (HRZ—Isoniazid, Rifampicin, and Pyrazinamide), Ethambutol is **not hepatotoxic**. Therefore, it is the drug of choice or a safer alternative when treating tuberculosis in patients with pre-existing chronic liver disease. **Analysis of Incorrect Options:** * **Kidney disease:** Since Ethambutol is mainly excreted via the renal route, it accumulates in renal failure, increasing the risk of dose-dependent toxicity (optic neuritis). Dosage adjustment or avoidance is necessary in renal impairment. * **Gout:** Ethambutol interferes with the renal excretion of uric acid, leading to **hyperuricemia**. This can precipitate an acute attack of gout, making it unsafe for these patients. * **Both liver and kidney disease:** While safe for the liver, its significant risk in renal failure makes this option incorrect. **High-Yield NEET-PG Pearls:** * **Mechanism of Action:** Inhibits **Arabinosyl transferase**, thereby blocking the synthesis of Arabinogalactan in the mycobacterial cell wall. * **Key Side Effect:** **Retrobulbar Optic Neuritis**, manifesting as decreased visual acuity and **Red-Green color blindness**. It is generally reversible upon discontinuation. * **Monitoring:** Monthly visual acuity and color vision testing are mandatory for patients on Ethambutol. * **Pediatric Note:** It is often avoided in young children (usually <6 years) because they cannot reliably report changes in visual acuity or color perception.

Question 1

Which of the following drugs is least commonly used as first -line therapy for uncomplicated urinary tract infections ?

Accepted Answer

Fluoroquinolones

Answer

Nitrofurantoin

Answer

Sulfonamides

Answer

Fosfomycin

Question 2

A wound swab reveals gram-positive cocci in clusters, catalase-positive, sensitive to Cefoxitin
and Oxacillin. What is the drug of choice?

Accepted Answer

Cloxacillin

Answer

Ceftriaxone

Answer

Vancomycin

Answer

Amoxicillin/Clavulanate

Question 3

Match the following antibiotic with its most commonly associated organism:

1. Streptomycin a. Streptococcal pharyngitis

2. Amoxicillin b. H. pylori

3. Doxycycline c. Mycobacterium tuberculosis

4. Clarithromycin d. Chlamydia trachomatis

Accepted Answer

1-c, 2-a, 3-d, 4-b

Answer

1-c, 2-b, 3-d, 4-a

Answer

1-a, 2-c, 3-b, 4-d

Answer

1-d, 2-a, 3-c, 4-b

Question 4

Regarding ESBL-producing organisms and their treatment, which of the following statements
are correct?
1. 1st generation cephalosporins such as Cefazolin retain activity against ESBL producers, unlike
3rd generation
2. Carbapenems have proven clinical efficacy against ESBL-producing organisms
3. The beta-lactamase enzyme responsible for ESBL resistance is encoded on transferable
plasmids
4. Piperacillin-Tazobactam is a reliable and effective alternative to Carbapenems

Accepted Answer

2, 3 and 4 only

Answer

1, 2 and 4 only

Answer

1, 2 and 3 only

Answer

1, 2, 3 and 4 all

Question 5

A patient is diagnosed with invasive mucormycosis following COVID-19 infection. Which of the
following antifungal agents has NO activity against Mucor species and should be avoided?

Accepted Answer

Voriconazole

Answer

Isavuconazole

Answer

Posaconazole

Answer

Liposomal Amphotericin B

Question 6

What is the mechanism of action of Pretomanid under the BPaLM regimen?

Accepted Answer

Inhibition of mycolic acid synthesis

Answer

Inhibition of ATP synthase

Answer

Inhibition of RNA polymerase

Answer

Inhibition of arabinoglycan synthesis

Question 7

Why does artemisinin-based combination therapy (ACT) reduce transmission of malaria more effectively than monotherapy?

Accepted Answer

It achieves faster parasite clearance reducing gametocyte production

Answer

It directly inhibits mosquito midgut development

Answer

It prevents sequestration of parasites

Answer

It kills gametocytes more rapidly

Question 8

Which of the following is a known side effect of zidovudine?

Accepted Answer

Granulocytopenia

Answer

Headache

Answer

Myalgia

Answer

Rashes

Question 9

Which of the following drug combinations demonstrates antimicrobial synergism?

Accepted Answer

Penicillin plus Streptomycin in subacute bacterial endocarditis

Answer

Ampicillin plus Tetracycline in endocarditis

Answer

Sulfamethoxazole plus Trimethoprim in urinary tract infections

Answer

Amphotericin B plus Flucytosine in cryptococcal meningitis

Question 10

Ethambutol is safer in a patient with which of the following conditions?

Accepted Answer

Liver disease

Answer

Kidney disease

Answer

Gout

Answer

Both liver and kidney disease

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?